The coronavirus illness 2019 (COVID-19) pandemic, brought on by extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is threatening folks’s lives and impacting their well being. It’s nonetheless unclear whether or not folks engaged in bodily exercise are at an elevated danger of SARS-CoV-2 an infection and extreme types of COVID-19.
To be able to present knowledge to assist reply this query, we, subsequently, investigated the results of endurance coaching on the degrees of host proteins concerned in SARS-CoV-2 an infection in mice. Eight-week-old C57BL/6J mice have been subjected to treadmill operating (17-25 m/min, 60-90 min, 5 classes/week, eight weeks).
After the intervention, the degrees of angiotensin-converting enzyme 2 (ACE2; host receptor for SARS-CoV-2), transmembrane protease serine 2 (TMPRSS2; host protease priming fusion of SARS-CoV-2 to host cell membranes), FURIN (host protease that promotes binding of SARS-CoV-2 to host receptors), and Neuropilin-1 (host coreceptor for SARS-CoV-2) have been measured in 10 organs that SARS-CoV-2 can infect (larynx, trachea, lung, coronary heart, jejunum, ileum, colon, liver, kidney, and testis).
Six organs (coronary heart, lung, jejunum, liver, trachea, and ileum) confirmed modifications within the ranges of at the very least one of many proteins. Endurance coaching elevated ACE2 ranges in coronary heart (+66.4%), lung (+37.1%), jejunum (+24.7%) and liver (+27.4%), and FURIN in liver (+17.9%) tissue. In distinction, endurance coaching decreased Neuropilin-1 ranges in liver (-39.7%), trachea (-41.2%), and ileum (-39.7%), and TMPRSS2 in lung (-11.3%). Taken collectively, endurance coaching altered the degrees of host proteins concerned in SARS-CoV-2 cell entry in an organ-dependent method.
A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 An infection and Its Software in a Inhabitants-Based mostly Survey by Mail
Noninvasive salivary antibody immunoassays can allow low-cost epidemiological surveillance of infections. This research concerned creating and validating a multiplex suspension immunoassay on the Luminex platform to measure immunoglobulin G (IgG) responses to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid and spike (S) proteins, and the spike protein’s S1 and S2 subunits and receptor binding area.
A number of variations of those recombinant proteins acquired from industrial and noncommercial sources have been evaluated. Assay growth and validation utilized saliva and serum samples from coronavirus illness 2019 (COVID-19) instances procured from industrial sources and damaging controls from a prepandemic survey.
Saliva was additionally collected in an illustration survey by mail involving grownup people in the US who have been recognized with SARS-CoV-2 an infection 15 to 80 days previous to pattern assortment. The survey had an 83% legitimate pattern return price (192 samples from 38 states).
Most COVID-19 instances (93%) reported mildly symptomatic or asymptomatic infections. The ultimate salivary assay primarily based on the best-performing spike and nucleocapsid proteins had a sensitivity of 87.1% (95% bootstrap confidence interval, 82.1 to 91.7%) and specificity of 98.5% (95.Zero to 100%) utilizing 227 and 285 saliva samples, respectively.
The identical assay had 95.9% (92.eight to 98.9%) sensitivity and 100% (98.Four to 100%) specificity in serum (174 and 285 serum samples, respectively). Salivary and serum antibody responses to spike and nucleocapsid proteins have been strongly correlated in 22 paired samples (r = 0.88 and r = 0.80, respectively). Antibody responses peaked at roughly 50 days postonset; higher sickness severity was related to stronger responses.
This research demonstrated {that a} salivary antibody assay can be utilized in large-scale inhabitants surveys by mail to raised characterize public well being impacts of COVID-19. IMPORTANCE Given the big impacts of the COVID-19 pandemic, creating instruments for inhabitants surveillance of an infection is of paramount significance.
This text describes the event of a multiplex immunoassay on a Luminex platform to measure salivary immunoglobulin G responses to the spike protein, its two subunits and receptor binding area, and the nucleocapsid protein of SARS-CoV-2. The assay validation utilized serum and saliva samples from prepandemic controls and up to date COVID-19 instances.
A survey by mail focusing on current COVID-19 instances throughout the US additionally demonstrated the utility of secure, at-home self-collection of saliva. By incorporating a number of SARS-CoV-2 proteins, this assay might differentiate responses to pure SARS-CoV-2 infections from responses to most vaccines.
Software of this noninvasive immunoassay in COVID-19 surveillance will help present estimates of cumulative incidence charges of symptomatic and asymptomatic infections in varied communities and subpopulations, temporal patterns of antibody responses, and danger components for an infection.
Roborovski hamster (Phodopus roborovskii) pressure SH101 as a systemic an infection mannequin of SARS-CoV-2
Extreme acute respiratory syndrome CoV-2 (SARS-CoV-2) is presently inflicting a worldwide menace with its unusually excessive transmission charges and fast evolution into various strains. In contrast to typical respiratory viruses, SARS-CoV-2 ceaselessly causes systemic an infection by breaking the boundaries of the respiratory methods.
The event of animal fashions recapitulating the medical manifestations of COVID-19 is of utmost significance not just for the event of vaccines and antivirals but additionally for understanding the pathogenesis. Nonetheless, there has not been developed an animal mannequin for systemic an infection of SARS-CoV-2 representing most features of the medical manifestations of COVID-19 with systemic signs.
Right here we report {that a} Roborovski hamster pressure SH101, a laboratory inbred hamster pressure of P. roborovskii, displayed most signs of systemic an infection upon SARS-CoV-2 an infection as within the case of the human counterpart, in contrast to present COVID-19 animal fashions.
Roborovski hamster pressure SH101 post-infection of SARS-CoV-2 represented most medical signs of COVID-19 resembling snuffling, labored respiratory, dyspnea, cough, hunched posture, progressive weight reduction, ruffled fur, and excessive fever following shaking chills.
Histological examinations additionally revealed preliminary right-predominated pneumonia in addition to slight organ damages within the mind and liver, manifesting systemic COVID-19 instances. Contemplating the advantage of a small animal in addition to its medical manifestations of SARS-CoV-2 an infection in human, this hamster mannequin appears to supply a perfect software to research COVID-19.
A mathematical mannequin for the dynamics of SARS-CoV-2 virus utilizing the Caputo-Fabrizio operator
The pandemic of SARS-CoV-2 virus stays a urgent problem with unpredictable traits which unfold worldwide via human interactions. The present research is specializing in the investigation and evaluation of a fractional-order epidemic mannequin that discusses the temporal dynamics of the SARS-CoV-2 virus in a group. It’s well-known that symptomatic and asymptomatic people have a significant impact on the dynamics of the SARS-CoV-2 virus subsequently, we divide the whole inhabitants into inclined, asymptomatic, symptomatic, and recovered teams of the inhabitants.
Additional, we assume that the vaccine confers everlasting immunity as a result of a number of vaccinations have commenced throughout the globe. The brand new fractional-order mannequin for the transmission dynamics of SARS-CoV-2 virus is formulated by way of the Caputo-Fabrizio fractional-order method with the upkeep of dimension in the course of the technique of fractionalization.
The speculation of mounted level will probably be used to point out that the proposed mannequin possesses a novel answer whereas the well-posedness (bounded-ness and positivity) of the fractional-order mannequin options are mentioned.
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-100ug |
QP13422-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-1mg |
QP13422-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-500ug |
QP13422-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS Associated Spike Mosaic S(N) |
7-07093 |
CHI Scientific |
100µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S(N) |
7-07094 |
CHI Scientific |
500µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S(N) |
7-07095 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S(M) |
7-07096 |
CHI Scientific |
100µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S(M) |
7-07097 |
CHI Scientific |
500µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S(M) |
7-07098 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S© |
7-07099 |
CHI Scientific |
100µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S© |
7-07100 |
CHI Scientific |
500µg |
Ask for price |
Recombinant SARS Associated Spike Mosaic S© |
7-07101 |
CHI Scientific |
1000µg |
Ask for price |
SARS Coronavirus Spike Mosaic Recombinant protein (Center) |
39-122 |
ProSci |
0.1 mg |
EUR 556.8 |
Description: SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
SARS Associated Spike Mosaic S(M) Protein |
20-abx260155 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
SARS Associated Spike Mosaic S(N) Protein |
20-abx260157 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
Recombinant (E.Coli) SARS Associated Spike Mosaic S |
RP-1422 |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
Recombinant (E.Coli) SARS Associated Spike Mosaic S |
RP-1423 |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
Recombinant (E.Coli) SARS Associated Spike Mosaic S |
RP-1424 |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
SARS Coronavirus Spike Mosaic Recombinant protein (C-terminus) |
39-123 |
ProSci |
0.1 mg |
EUR 556.8 |
Description: SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
SARS Coronavirus Spike Mosaic Recombinant protein (N-terminus) |
39-124 |
ProSci |
0.1 mg |
EUR 556.8 |
Description: SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
Recombinant SARS Spike Mosaic Protein S (N-Terminal) |
VAng-Lsx0073-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS spike mosaic protein S (N-terminal), recombinant protein from E. coli. |
SARS-CoV-2 (COVID-19) Nucleocapsid Mosaic Recombinant protein |
39-115 |
ProSci |
0.05 mg |
EUR 556.8 |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
SARS-CoV-2 (COVID-19) Spike E Mosaic Recombinant protein |
39-114 |
ProSci |
0.05 mg |
EUR 556.8 |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
Recombinant SARS Spike Mosaic S Protein (aa 408-470, 540-573) |
VAng-Lsx0056-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant SARS-CoV Spike protein containing 408-470, 540-573 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique. |
Recombinant SARS Spike Mosaic S Protein (aa 12-53, 90-115, 171-203) |
VAng-Lsx0055-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant SARS-CoV Spike protein containing 12-53, 90-115, 171-203 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique. |
Recombinant SARS Spike Mosaic S Protein (aa 1051-1076, 1121-1154, 1162-1190) |
VAng-Lsx0057-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant SARS-CoV Spike protein containing 1051-1076, 1121-1154, 1162-1190 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique. |
Cytomegalo Virus Mosaic |
PR27123 |
Neuromics |
500 ug |
EUR 999.6 |
SARS Antibody |
1-CSB-PA020709GA01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
SARS Antibody |
1-CSB-PA04145A0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
SARS siRNA |
20-abx932473 |
Abbexa |
|
|
|
SARS siRNA |
20-abx932474 |
Abbexa |
|
|
|
SARS antibody |
70R-20086 |
Fitzgerald |
50 ul |
EUR 522 |
Description: Rabbit polyclonal SARS antibody |
SARS antibody |
70R-1444 |
Fitzgerald |
100 ug |
EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the C terminal of SARS |
SARS antibody |
70R-1445 |
Fitzgerald |
100 ug |
EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the middle region of SARS |
SARS antibody |
39139-100ul |
SAB |
100ul |
EUR 302.4 |
SARS siRNA |
20-abx904776 |
Abbexa |
|
|
|
Turnip mosaic virus Polyprotein |
1-CSB-EP2708TJM |
Cusabio |
-
EUR 733.20
-
EUR 370.80
-
EUR 2192.40
-
EUR 1126.80
-
EUR 1461.60
-
EUR 476.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Turnip mosaic virus Polyprotein,partial expressed in E.coli |
Recombinant Malaria Cs Mosaic |
7-07090 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Malaria Cs Mosaic |
7-07091 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Malaria Cs Mosaic |
7-07092 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant Cytomegalo Virus Mosaic |
7-07525 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Cytomegalo Virus Mosaic |
7-07526 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Cytomegalo Virus Mosaic |
7-07527 |
CHI Scientific |
1000µg |
Ask for price |
HTLV-1 Mosaic Protein |
20-abx260286 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1930.80
|
|
|
Malaria Cs Mosaic Protein |
20-abx260295 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1930.80
|
|
|
Rubella Virus E1 Mosaic |
PR27125 |
Neuromics |
500 ug |
EUR 999.6 |
Recombinant HEV Mosaic Protein |
VAng-Lsx0225-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: HEV Mosaic Protein, recombinant protein from E. coli. |
Cucumber mosaic virus Helicase (ORF1a) |
1-CSB-CF2240CMV |
Cusabio |
-
EUR 1158.00
-
EUR 798.00
-
EUR 858.00
|
|
|
Description: Recombinant Cucumber mosaic virus Helicase(ORF1a) expressed in in vitro E.coli expression system |
Recombinant Treponema pallidum p41 Mosaic |
7-07570 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Treponema pallidum p41 Mosaic |
7-07571 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Treponema pallidum p41 Mosaic |
7-07572 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant Rubella Virus E1 Mosaic |
7-07858 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Rubella Virus E1 Mosaic |
7-07859 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Rubella Virus E1 Mosaic |
7-07860 |
CHI Scientific |
1000µg |
Ask for price |
HCV NS4 mosaic recombinant antigen |
00155-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
HCV NS4 mosaic recombinant antigen |
00155-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
Cucumber Mosaic Virus ELISA Kit |
abx157282-96tests |
Abbexa |
96 tests |
EUR 801.6 |
|
Rubella Virus E1 Mosaic Protein |
abx060646-1mg |
Abbexa |
1 mg |
EUR 2214 |
|
Rubella Virus E1 Mosaic Protein |
abx060647-1mg |
Abbexa |
1 mg |
EUR 1796.4 |
|
Treponema pallidum p41 Mosaic Protein |
20-abx260173 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
Rubella Virus E1 Mosaic Protein |
20-abx260310 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1930.80
|
|
|
Recombinant EBV P18 Mosaic Protein |
VAng-Lsx0115-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: EBV P18 Mosaic protein, recombinant protein from E. coli. |
Recombinant HEV Mosaic-S Protein |
VAng-Lsx0226-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: HEV Mosaic-S Protein, recombinant protein from E. coli. |
Recombinant HTLV Mosaic Protein [GST] |
VAng-Lsx0304-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant HTLV protein fused with GST at N-terminus was expressed in E. coli and purified by proprietary chromatographic technique. |
Recombinant HTLV-1 Mosaic Protein |
VAng-Lsx0310-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: HTLV type 1 Mosaic Protein, recombinant protein from E. coli. |
Recombinant MeV Hemagglutinin Mosaic Protein |
VAng-Lsx0386-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant MeV HA protein containing the large hemagglutinin immunodominant regions 1-30, 115-150 and 379-410 amino acids was expressed in E. coli and purified by proprietary chromatographic technique. |
Recombinant MeV Fusion Mosaic Protein |
VAng-Lsx0387-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: MeV Fusion Mosaic protein, recombinant protein from E. coli. |
Recombinant RuV E1 Mosaic Protein |
VAng-Lsx0488-100g |
Creative Biolabs |
100 µg |
EUR 1155.6 |
Description: RuV E1 Mosaic, recombinant protein from E. coli. |
Recombinant RuV E1 Mosaic Protein |
VAng-Lsx0488-1mg |
Creative Biolabs |
1 mg |
EUR 2587.2 |
Description: RuV E1 Mosaic, recombinant protein from E. coli. |
Recombinant RuV E1 Mosaic Protein |
VAng-Lsx0488-500g |
Creative Biolabs |
500 µg |
EUR 1892.4 |
Description: RuV E1 Mosaic, recombinant protein from E. coli. |
Recombinant SARS SARS Core Protein, Untagged, E.coli-100ug |
QP10499-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg |
QP10499-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-500ug |
QP10499-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-100ug |
QP13416-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg |
QP13416-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-500ug |
QP13416-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS Envelope Protein, Untagged, E.coli-100ug |
QP13417-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Envelope Protein, Untagged, E.coli-1mg |
QP13417-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Envelope Protein, Untagged, E.coli-500ug |
QP13417-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS Matrix Protein, Untagged, E.coli-100ug |
QP13418-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Matrix Protein, Untagged, E.coli-1mg |
QP13418-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Matrix Protein, Untagged, E.coli-500ug |
QP13418-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS MERS Protein, His, E.coli-100ug |
QP13419-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS MERS Protein, His, E.coli-1mg |
QP13419-1mg |
EnQuireBio |
1mg |
EUR 1513.2 |
Recombinant SARS SARS MERS Protein, His, E.coli-500ug |
QP13419-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS-CoV Protein, His, E.coli-1mg |
QP13423-1mg |
EnQuireBio |
1mg |
EUR 4744.8 |
Recombinant SARS SARS-CoV Protein, His, E.coli-20ug |
QP13423-20ug |
EnQuireBio |
20ug |
EUR 241.2 |
Recombinant SARS SARS-CoV Protein, His, E.coli-5ug |
QP13423-5ug |
EnQuireBio |
5ug |
EUR 186 |
SARS Conjugated Antibody |
C39139 |
SAB |
100ul |
EUR 476.4 |
SARS cloning plasmid |
CSB-CL020709HU1-10ug |
Cusabio |
10ug |
EUR 451.2 |
|
Description: A cloning plasmid for the SARS gene. |
SARS cloning plasmid |
CSB-CL020709HU2-10ug |
Cusabio |
10ug |
EUR 451.2 |
|
Description: A cloning plasmid for the SARS gene. |
anti- SARS antibody |
FNab07609 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against SARS |
SARS Spike Peptide |
3219P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) SARS Spike peptide |
SARS Rabbit pAb |
A13350-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SARS Rabbit pAb |
A13350-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SARS Rabbit pAb |
A13350-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SARS Rabbit pAb |
A13350-50ul |
Abclonal |
50 ul |
EUR 267.6 |
SARS Spike Antibody |
24216-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24217-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24218-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24219-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24318-100ul |
SAB |
100ul |
EUR 468 |
SARS Matrix Antibody |
24319-100ul |
SAB |
100ul |
EUR 468 |
SARS Matrix Antibody |
24320-100ul |
SAB |
100ul |
EUR 468 |
SARS Envelope Antibody |
24321-100ul |
SAB |
100ul |
EUR 468 |
SARS Envelope Antibody |
24322-100ul |
SAB |
100ul |
EUR 468 |
SARS Blocking Peptide |
33R-7048 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SARS antibody, catalog no. 70R-1444 |
SARS Spike Peptide |
3525P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) SARS Spike peptide |
SARS Matrix Peptide |
3527P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) SARS Matrix peptide |
SARS Matrix Peptide |
3529P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) SARS Matrix peptide |
SARS Envelope Peptide |
3531P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) SARS Envelope peptide |
SARS Envelope Peptide |
3533P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) SARS Envelope peptide |
SARS Blocking Peptide |
33R-8713 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SARS antibody, catalog no. 70R-1445 |
SARS Coronavirus antibody |
10C-CR9003M1 |
Fitzgerald |
100 ug |
EUR 598.8 |
Description: Mouse monoclonal SARS Coronavirus antibody |
SARS Nucleocapsid antibody |
10R-10470 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
SARS Nucleocapsid antibody |
10R-10471 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
SARS E2 antibody |
10R-1976 |
Fitzgerald |
100 ul |
EUR 289.2 |
Description: Mouse monoclonal SARS E2 antibody |
SARS M antibody |
10R-1977 |
Fitzgerald |
100 ul |
EUR 289.2 |
Description: Mouse monoclonal SARS M antibody |
SARS Spike Antibody |
20-abx137184 |
Abbexa |
-
EUR 1262.40
-
EUR 1846.80
-
EUR 2064.00
|
|
|
SARS Nucleocapsid Antibody |
20-abx137185 |
Abbexa |
-
EUR 1262.40
-
EUR 1846.80
-
EUR 2364.00
|
|
|
SARS Spike Antibody |
20-abx137200 |
Abbexa |
-
EUR 1412.40
-
EUR 2264.40
-
EUR 2665.20
|
|
|
SARS Nucleocapsid Antibody |
20-abx137201 |
Abbexa |
-
EUR 1412.40
-
EUR 2264.40
-
EUR 2665.20
|
|
|
SARS-E2 Antibody |
abx016055-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
SARS-M Antibody |
abx016056-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
SARS Rabbit pAb |
A6733-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SARS Rabbit pAb |
A6733-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SARS Rabbit pAb |
A6733-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SARS Rabbit pAb |
A6733-50ul |
Abclonal |
50 ul |
EUR 267.6 |
SARS Protease Substrate |
H-5982.0500 |
Bachem |
0.5mg |
EUR 356.4 |
Description: Sum Formula: C66H119N21O22S; CAS# [587886-51-9] net |
SARS Protease Substrate |
H-5982.1000 |
Bachem |
1.0mg |
EUR 618 |
Description: Sum Formula: C66H119N21O22S; CAS# [587886-51-9] net |
Anti-SARS antibody |
STJ28816 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts. Multiple alternatively spliced transcript variants have been described but the biological validity of all variants is unknown. |
Anti-SARS antibody |
STJ115313 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts. Multiple alternatively spliced transcript variants have been described but the biological validity of all variants is unknown. |
SARS Polyclonal Antibody |
A71293-050 |
EpiGentek |
50 ul |
EUR 302.5 |
SARS Polyclonal Antibody |
A71293-100 |
EpiGentek |
100 ul |
EUR 423.5 |
Anti-SARS (1H4) |
YF-MA10816 |
Abfrontier |
100 ug |
EUR 435.6 |
Description: Mouse monoclonal to SARS |
SARS Polyclonal Antibody |
A53977-020 |
EpiGentek |
20 ul |
EUR 117.7 |
SARS Polyclonal Antibody |
A53977-050 |
EpiGentek |
50 ul |
EUR 302.5 |
SARS Polyclonal Antibody |
A53977-100 |
EpiGentek |
100 ul |
EUR 423.5 |
SARS Polyclonal Antibody |
A53977 |
EpiGentek |
-
EUR 684.66
-
EUR 117.70
-
EUR 302.50
-
EUR 423.50
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
Recombinant (E.Coli) Circumsporozoite (CSP) mosaic protein (107-129, 334-351 aa) (P.falciparum) mosaic protein |
CSPF16-R |
Alpha Diagnostics |
50 ug |
EUR 416.4 |
Recombinant P. Falciparum Circumsporozoite Mosaic protein |
DAG1344 |
Creative Diagnostics |
100 µg |
EUR 774 |
Recombinant Herpes Simplex Virus-8 Mosaic |
7-07138 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Herpes Simplex Virus-8 Mosaic |
7-07139 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Herpes Simplex Virus-8 Mosaic |
7-07140 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant Hepatitis C Virus NS4 Mosaic |
7-07300 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Hepatitis C Virus NS4 Mosaic |
7-07301 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Hepatitis C Virus NS4 Mosaic |
7-07302 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 gp120 nef Mosaic |
7-07657 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 gp120 nef Mosaic |
7-07658 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 gp120 nef Mosaic |
7-07659 |
CHI Scientific |
1000µg |
Ask for price |
HTLV-1 virus mosaic recombinant antigen |
00205-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. |
HTLV-1 virus mosaic recombinant antigen |
00205-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. |
HHV-4 recombinant mosaic EBNA1 antigen |
00212-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HHV-4 recombinant mosaic EBNA1 antigen. Region: 1-90/408-498aa |
HHV-4 recombinant mosaic EBNA1 antigen |
00212-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HHV-4 recombinant mosaic EBNA1 antigen. Region: 1-90/408-498aa |
Rubella virus E1 mosaic recombinant antigen |
00215-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: Rubella virus E1 mosaic recombinant antigen a.a. 157-176/374-390/213-239. |
Rubella virus E1 mosaic recombinant antigen |
00215-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: Rubella virus E1 mosaic recombinant antigen a.a. 157-176/374-390/213-239. |
Hepatitis C Virus NS4 Mosaic Protein |
20-abx260127 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
HIV-1 gp120 nef Mosaic Protein |
20-abx260272 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1930.80
|
|
|
Herpes Simplex Virus-8 Mosaic Protein |
20-abx260329 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1930.80
|
|
|
Recombinant HEV Mosaic ORF2, ORF3 Protein |
VAng-Lsx0223-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: HEV Mosaic ORF2, ORF3, recombinant protein from E. coli. |
Recombinant (E.Coli) Treponema pallidum p41 Mosaic |
RP-1445 |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
Recombinant HTLV gp 46 Mosaic Protein |
VAng-Lsx0303-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant HTLV gp46 protein containing the gp46 immunodominant regions, 162-214 amino acids and 242-257 amino acids was expressed in E. coli and purified by proprietary chromatographic technique. |
Recombinant RuV E1 Mosaic Protein [His] |
VAng-Lsx0489-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: RuV E1 Mosaic [His], recombinant protein from E. coli. |
SARS Antibody, HRP conjugated |
1-CSB-PA04145B0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
SARS Antibody, FITC conjugated |
1-CSB-PA04145C0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
SARS Antibody, Biotin conjugated |
1-CSB-PA04145D0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Human SARS shRNA Plasmid |
20-abx954245 |
Abbexa |
|
|
|
Mouse SARS shRNA Plasmid |
20-abx972567 |
Abbexa |
|
|
|
Rat SARS shRNA Plasmid |
20-abx988123 |
Abbexa |
|
|
|
SARS-CoV Spike Antibody |
3219-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS (IN1) Spike Peptide |
3221P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) SARS (IN1) Spike peptide |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS (IN2) Spike Peptide |
3223P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) SARS (IN2) Spike peptide |
SARS-CoV Spike Antibody |
3225-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS (IN3) Spike Peptide |
3225P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) SARS (IN3) Spike peptide |
SARS-CoV Matrix Antibody |
3527-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
3527-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
The regular states of the mannequin are analyzed and the sensitivity evaluation of the fundamental reproductive quantity is explored. Furthermore to parameterize the mannequin an actual knowledge of SARS-CoV-2 virus reported within the Sultanate of Oman from January 1st, 2021 to Could 23rd, 2021 are used. We then carry out the massive scale numerical findings to point out the validity of the analytical work.